Tumor necrosis factor inhibitors enhance corticosteroid therapy for stevens-johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study

HIGHLIGHTS

• What: This study evaluates the effectiveness and safety of combination therapy with corticosteroids and tumor necrosis factor inhibitors (TNFi) in treating irEN patients. Specifically, the authors seek to determine if this approach accelerates skin re-epithelization, reduces corticosteroid exposure, and decreases acute mortality rates, without increasing major treatment-related adverse events compared to corticosteroid monotherapy. The research has deceased patients maintained higher SF, IL-6, and TNF-a levels, and lower lymphocyte subset counts. This study has pinpointed potential risk factors associated with mortality in patients with irEN, including low BMI, high SCORTEN, sustained elevation of inflammatory . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.